<DOC>
	<DOCNO>NCT02697851</DOCNO>
	<brief_summary>This study investigate pharmacokinetic evotaz ( atazanavir/cobicistat ) microgynon ( ethinylestradiol/levonorgestrel ) administer alone together . There two study arm , take medication different order : GROUP 1 : Microgynon 30® 21 day , Followed Microgynon 30® 21 day plus Evotaz® 14 day , Followed Evotaz® 14 day GROUP 2 : Evotaz® 14 day follow 7 day wash-out , Followed Microgynon 30® 21 day plus Evotaz® 14 day , Followed Microgynon 30® 14 day ( participant may choose complete 21 day pack ) . The total duration study 57 day ( +screening follow visit ) patient 3 intensive pharmacokinetic day day 14 , 35 56 .</brief_summary>
	<brief_title>Pharmacokinetic Effect Evotaz/Microgynon Co-administration</brief_title>
	<detailed_description>Protocol Number : SSAT069 EudraCT Number : 2015-004799-30 Name Investigational Product : Microgynon 30® ; Evotaz® Name active ingredient : Ethinylestradiol , levonorgestrel ; atazanavir , cobicistat Study title : The effect atazanavir/cobicistat pharmacokinetics oral contraceptive contain ethinylestradiol levonorgestrel ( Microgynon 30® ) healthy woman Phase study : Phase I Objectives : The objective study : Primary -To ass pharmacokinetics ethinylestradiol/levonorgestrel atazanavir/cobicistat co-administration HIV negative female healthy volunteer Secondary - To assess safety tolerability ethinylestradiol/levonorgestrel atazanavir/cobicistat co-administered HIV negative female healthy volunteer - To investigate association genetic polymorphism drug disposition gene drug exposure Study design : 57 day ( exclude screen follow ) , open label , cross-over , pharmacokinetic study Indication : Not applicable Methodology : Measurements steady state pharmacokinetic profile plasma ethinylestradiol/levonorgestrel atazanavir/cobicistat Planned sample size : Up 30 female healthy volunteer enrol baseline order achieve 18 complete study Summary eligibility criterion : Healthy female participant determine medical history , physical examination , 12-lead electrocardiogram , clinical laboratory evaluation eligible participate study . Women childbearing potential must nurse pregnant . Women childbearing potential must negative pregnancy test screening . Number study centre : One Duration treatment : 57 day ( exclude screen follow visit ) Dose route administration : All participant administer Microgynon 30® ( ethinylestradiol/levonorgestrel 30 micrograms/150 microgram ) Evotaz® ( atazanavir 300 mg/cobicistat 150 mg ) follow : GROUP 1 : Microgynon 30® 21 day Followed Microgynon 30® 21 day plus Evotaz® 14 day Followed Evotaz® 14 day GROUP 2 : Evotaz® 14 day follow 7 day wash-out Followed Microgynon 30® 21 day plus Evotaz® 14 day Followed Microgynon 30® 14 day ( participant may choose complete 21 day pack ) Criteria evaluation : Pharmacokinetic parameter ethinylestradiol/levonorgestrel atazanavir/cobicistat evaluate blood drawn day 14 , 35 56 0 ( pre-dose ) , 1 , 2 , 4 , 6 , 8 , 10 , 12 , 24 hour post dose Safety tolerability medication also assess question , physical examination laboratory parameter . These perform regular interval drug study . Primary Endpoint : Steady state plasma concentration ethinylestradiol/levonorgestrel atazanavir/cobicistat co-administration HIV negative female healthy volunteer Secondary End point : Safety tolerability study drug co-administration Relationship genetic polymorphism exposure study drug</detailed_description>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Ethinyl estradiol , levonorgestrel drug combination</mesh_term>
	<mesh_term>Ethinyl Estradiol-Norgestrel Combination</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<criteria>Participants must meet follow inclusion criterion within 28 day prior baseline visit : 1 . The ability understand sign write informed consent form , prior participation screening procedure must willing comply study requirement 2 . Nonpregnant , nonlactating female . 3 . Between 18 35 year , inclusive 4 . Body Mass Index ( BMI ) 18 35 kg/m2 , inclusive 5 . ALT , alkaline phosphatase bilirubin ≤ 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . A single repeat allow eligibility determination . 6 . Women childbearing potential ( WOCBP ) must use additional adequate method contraception avoid pregnancy throughout study period least 4 week study ( include one list , hormonebased contraception allow study ) A female may eligible enter participate study : 1. nonchildbearing potential define physically incapable become pregnant document tubal ligation , hysterectomy bilateral oophorectomy , 2. childbearing potential reliable negative pregnancy test Screening Day 1 risk agrees use one follow method contraception avoid pregnancy screening , throughout study , least 4 week discontinuation study medication : Complete abstinence penilevaginal intercourse Double barrier method ( male condom/spermicide , male condom/diaphragm , diaphragm/spermicide ) ; Any intrauterine device ( IUD ) publish data show expected failure rate &lt; 1 % per year ( please note IUDs meet criterion ) Male partner sterilization confirm prior female subject 's entry study , male sole partner subject ; Any method publish data show expected failure rate &lt; 1 % per year contain hormone . Any contraception method must use consistently , accordance approve product label least four week discontinuation IMP . 7 . Willing consent personal detail enter onto TOPS database 8 . Willing provide proof identity photographic ID screen subsequent visit 9 . Registered GP UK Participants meet follow exclusion criterion enrol study . 1 . Any clinically significant acute chronic medical illness 2 . Evidence organ dysfunction clinically significant deviation normal physical examination , vital sign , ECG clinical laboratory determination 3 . Positive blood screen hepatitis B surface antigen C antibody 4 . Positive blood screen HIV1 2 antibody/antigen assay 5 . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) 6 . Any medical contraindication use combine oral contraceptive . 7 . History presence allergy oral contraceptive , atazanavir cobicistat excipients ( sodium methyl parahydroxybenzoate , lactulose , Hypromellose Colloidal silicon dioxide , Silicified microcrystalline cellulose Crospovidone , Magnesium stearate , Polyvinyl alcohol partially hydrolyse , Macrogol 3350 , Titanium dioxide , Talc , Iron oxide red , Iron oxide black , Lactose monohydrate , Magnesium stearate , Gelatine Yellow iron oxide , Indigocarmin ( E132 ) , White ink , Shellac , Titanium dioxide ( E171 ) , Ammonium hydroxide , Propylene glycol , Simethicone , Hypromellose , Polyvinyl alcohol partially hydrolyse , Macrogol 3350 ) 8 . Current recent ( within three month ) gastrointestinal disease 9 . Known intolerance lactose monohydrate , sunset yellow aluminium lake ( E110 ) , patient galactose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption 10 . Clinically relevant alcohol drug use ( positive urine drug screen ) history alcohol drug use consider Investigator sufficient hinder compliance treatment , followup procedure evaluation adverse event . Smoking permit , tobacco intake remain consistent throughout study 11 . Exposure investigational drug ( placebo ) participation clinical study involve donation blood sample within three month first dose study drug 12 . Use medical product contain estrogen and/or progesteron , include IUS , implant etc . 4 week screen 13 . Use drug ( unless approve Investigator ) , include overthecounter medication herbal preparation , within two week prior first dose study drug , unless approved/prescribed Principal Investigator know interact study drug 14 . Females childbearing potential without use effective nonhormonal birth control method , willing continue practise birth control method least four week end treatment period</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>